Orchard Therapeutics announces first patient dosed with cryopreserved formulation of OTL-1
Orchard Therapeutics announced that the first patient with Wiskott-Aldrich Syndrome has been dosed in a open label study designed to evaluate engraftment of the cryopreserved formulation of OTL-103, its ex vivo autologous hematopoietic stem cell gene therapy. April 25, 2019